Cipaglucosidase Alfa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Cipaglucosidase Alfa. Educational only — not medical advice.
Labeled uses
POMBILITI is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).
Source: FDA labeling via NIH DailyMed (set d77aa596…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.